Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: Evidence for augmented biosynthesis

Schizophrenia Research

Volumn 107, Issue 2-3, 2009, Pages 150-157

  McNamara, Robert K ^a   Able, Jessica A ^a   Jandacek, Ronald ^a   Rider, Therese ^a   Tso, Patrick ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

9 OH RISP; Arachidonic acid; Docosahexaenoic acid; Erythrocyte; Omega 3 fatty acid; Prefrontal cortex; Rat; Risperidone

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; LINOLENIC ACID; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BODY WEIGHT; BRAIN LEVEL; CHRONIC DISEASE; CONTROLLED STUDY; DIETARY INTAKE; DRUG BLOOD LEVEL; ERYTHROCYTE; ERYTHROCYTE LEVEL; FATTY ACID ANALYSIS; GAS CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; LONG TERM CARE; MALE; MENTAL DISEASE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RAT; SCHIZOPHRENIA; TREATMENT OUTCOME;

ALPHA-LINOLENIC ACID; ANIMALS; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACIDS; ERYTHROCYTES; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; MALE; PREFRONTAL CORTEX; RATS; RATS, LONG-EVANS; RISPERIDONE;

EID: 58249088139     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.09.027     Document Type: Article

References (52)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 (1999) 1686-1696
2. Amminger G.P., Schaefer M.R., and McGorry P.D. Omega-3 fatty acids reduce the risk of early transition to psychosis in ultra-high risk individuals: a double-blind randomized, placebo-controlled treatment study. International Conference of Schizophrenia Research (2007)
3. Arterburn L.M., Hall E.B., and Oken H. Distribution, interconversion, and dose response of omega-3 fatty acids in humans. Am. J. Clin. Nutr. 83 6 Suppl (2006) 1467S-1476S
4. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., Bennett C., Ranjekar P.K., and Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 53 (2003) 56-64
5. Bakewell L., Burdge G.C., and Calder P.C. Polyunsaturated fatty acid concentrations in young men and women consuming their habitual diets. Br. J. Nutr. 96 (2006) 93-99
6. Berger G.E., Proffitt T.M., McConchie M., Yuen H., Wood S.J., Amminger G.P., Brewer W., and McGorry P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J. Clin. Psychiatry 68 12 (2007) 1867-1875
7. Brown S., Birtwistle J., Roe L., and Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 29 (1999) 697-701
8. Caniato R.N., Alvarenga M.E., and Garcia-Alcaraz M.A. Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine. Aust. N. Z. J. Psychiatry 40 (2006) 691-697
9. Childs C.E., Romeu-Nadal M., Burdge G.C., and Calder P.C. Gender differences in the omega-3 fatty acid content of tissues. Proc. Nutr. Soc. 67 (2008) 19-27
10. Connor W.E., Neuringer M., and Lin D.S. Dietary effects on brain fatty acid composition: the reversibility of omega-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. J. Lipid Res. 31 (1990) 237-247
11. Contreras M.A., and Rapoport S.I. Recent studies on interactions between n-3 and n-6 polyunsaturated fatty acids in brain and other tissues. Curr. Opin. Lipidol. 13 3 (2002) 267-272
12. Emsley R., Myburgh C., Oosthuizen P., and van Rensburg S.J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 159 (2002) 1596-1598
13. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., and Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot. Essent. Fat. Acids 69 (2003) 393-399
14. Fell M.J., Anjum N., Dickinson K., Marshall K.M., Peltola L.M., Vickers S., Cheetham S., and Neill J.C. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology 194 (2007) 221-231
15. Fenton W.S., Dickerson F., Boronow J., Hibbeln J.R., and Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 158 (2001) 2071-2074
16. Giltay E.J., Gooren L.J., Toorians A.W., Katan M.B., and Zock P.L. Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects. Am. J. Clin. Nutr. 80 (2004) 1167-1174
17. Harris W.S. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J. Lipid Res. 30 (1989) 785-807
18. Henderson D.C., Cagliero E., Copeland P.M., Borba C.P., Evins E., Hayden D., Weber M.T., Anderson E.J., Allison D.B., Daley T.B., Schoenfeld D., and Goff D.C. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch. Gen. Psychiatry 62 (2005) 19-28
19. Henderson D.C., Borba C.P., Daley T.B., Boxill R., Nguyen D.D., Culhane M.A., Louie P., Cather C., Eden Evins A., Freudenreich O., Taber S.M., and Goff D.C. Dietary intake profile of patients with schizophrenia. Ann. Clin. Psychiatry 18 (2006) 99-105
20. Hibbeln J.R., Makino K.K., Martin C.E., Dickerson F., Boronow J., and Fenton W.S. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol. Psychiatry 53 (2003) 431-441
21. Horrobin D.F., Manku M.S., Hillman H., Iain A., and Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry 30 (1991) 795-805
22. Igarashi M., Ma K., Chang L., Bell J.M., and Rapoport S.I. Dietary omega-3 PUFA deprivation for 15 weeks upregulates elongase and desaturase expression in rat liver but not brain. J. Lipid Res. 48 (2007) 2463-2470
23. Kaddurah-Daouk R., McEvoy J., Baillie R.A., Lee D., Yao J.K., Doraiswamy P.M., and Krishnan K.R. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry 12 (2007) 934-945
24. Kale A., Joshi S., Naphade N., Sapkale S., Raju M.S., Pillai A., Nasrallah H., and Mahadik S.P. Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients. Schizophr. Res. 98 (2008) 295-301
25. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., and Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 58 (2002) 1-10
26. Krause C., Rosewich H., Thanos M., and Gartner J. Identification of novel mutations in PEX2, PEX6, PEX10, PEX12, and PEX13 in Zellweger spectrum patients. Hum. Mutat. 27 (2006) 1157-1165
27. Leng G.C., Horrobin D.F., Fowkes F.G., Smith F.B., Lowe G.D., Donnan P.T., and Ells K. Plasma essential fatty acids, cigarette smoking, and dietary antioxidants in peripheral arterial disease. A population-based case-control study. Arterioscler. Thromb. 14 (1994) 471-478
28. Leonard A.E., Bobik E.G., Dorado J., Kroeger P.E., Chuang L.T., Thurmond J.M., Parker-Barnes J.M., Das T., Huang Y.S., and Mukerji P. Cloning of a human cDNA encoding a novel enzyme involved in the elongation of long-chain polyunsaturated fatty acids. Biochem. J. 350 (2000) 765-770
29. Levant B., Crane J.F., and Carlson S.E. Sub-chronic antipsychotic drug treatment does not alter brain phospholipid fatty acid composition in rats. Prog. Neuro-psychopharmacol. Biol. Psychiatry 30 (2006) 728-732
30. Lewis, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am. J. Hum. Genet. 73 (2003) 34-48
31. Mauri M.C., Volonteri L.S., Colasanti A., Fiorentini A., De Gaspari I.F., and Bareggi S.R. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin. Pharmacokinet. 46 (2007) 359-388
32. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., Germano D., Bravin J., McDonald T., Blair A., Adlard S., and Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 59 10 (2002) 921-928
33. McNamara R.K., Jandacek R., Rider T., Tso P., Hahn C.G., Richtand N.M., and Stanford K.E. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophr. Res. 91 (2007) 37-50
34. McNamara R.K., Sullivan J., and Richtand N.M. Omega-3 fatty acid deficiency augments amphetamine-induced behavioral sensitization in adult mice: prevention by chronic lithium treatment. J. Psychiatr. Res. 42 (2008) 458-468
35. McNamara R.K., Jandacek R., Rider T., Tso P., Stanford K.E., Hahn C.G., and Richtand N.M. Deficits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res. 160 (2008) 285-299
36. Metcalfe L.D., Schmitz A.A., and Pelka J.R. Rapid preparation of fatty acid esters from lipids for gas chromatographic analysis. Anal. Chem. 38 (1966) 514-515
37. Meyer J.M., and Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 70 (2004) 1-17
38. Myers C.S., Contreras M.A., Chang M.C., Rapoport S.I., and Appel N.M. Haloperidol downregulates phospholipase A(2) signaling in rat basal ganglia circuits. Brain Res. 896 (2001) 96-101
39. Nettleton J.A., and Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J. Am. Diet. Assoc. 105 (2005) 428-440
40. Parikh V., Khan M.M., and Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 37 (2003) 43-51
41. Pawlosky R.J., Hibbeln J.R., Novotny J.A., and Salem Jr. N. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J. Lipid Res. 42 (2001) 1257-1265
42. Pawlosky R.J., Bacher J., and Salem N. Ethanol consumption alters electroretinograms and depletes neural tissues of docosahexaenoic acid in rhesus monkeys: nutritional consequences of a low omega-3 fatty acid diet. Alcohol. Clin. Exp. Res. 25 (2001) 1758-1765
43. Peet M., Brind J., Ramchand C.N., Shah S., and Vankar G.K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. 49 (2001) 243-251
44. Reddy R.D., Keshavan M.S., and Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. 30 (2004) 901-911
45. Rzehak P., Heinrich J., Klopp N., Schaeffer L., Hoff S., Wolfram G., Illig T., and Linseisen J. Evidence for an association between genetic variants of the fatty acid desaturase 1 fatty acid desaturase 2 (FADS1 FADS2) gene cluster and the fatty acid composition of erythrocyte membranes. Br. J. Nutr. 15 (2008) 1-7
46. Schaeffer L., Gohlke H., Muller M., Heid I.M., Palmer L.J., Kompauer I., Demmelmair H., Illig T., Koletzko B., and Heinrich J. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum. Mol. Genet. 15 (2006) 1745-1756
47. Strassnig M., Singh Brar J., and Ganguli R. Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. Schizophr. Res. 76 (2005) 343-351
48. Trzeciak H.I., Kalaciński W., Małecki A., and Kokot D. Effect of neuroleptics on phospholipase A2 activity in the brain of rats. Eur. Arch. Psychiatry Clin. Neurosci. 245 3 (1995) 179-182
49. Vik-Mo A.O., Birkenaes A.B., Fernø J., Jonsdottir H., Andreassen O.A., and Steen V.M. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int. J. Neuropsychopharmacol. 11 (2008) 679-684
50. Williard D.E., Nwankwo J.O., Kaduce T.L., Harmon S.D., Irons M., Moser H.W., Raymond G.V., and Spector A.A. Identification of a fatty acid delta6-desaturase deficiency in human skin fibroblasts. J. Lipid Res. 42 4 (2001) 501-508
51. Xiao Y., Huang Y., and Chen Z.Y. Distribution, depletion and recovery of docosahexaenoic acid are region-specific in rat brain. Br. J. Nutr. 94 (2005) 544-550
52. Yao J.K., Leonard S., and Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 42 (2000) 7-17